To the full analysis
McKesson stock: growth
MCKMcKesson reported $403.43B in revenue for fiscal 2026, up 12.4% on the prior year, up 11.1% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
8%
per year from 2007 to 2026, per share 13.2%
Earnings (Annual rate)
8.8%
per year from 2007 to 2026, per share 14.3%
Free cash flow (Annual rate)
8.1%
per year from 2007 to 2026, per share 13.2%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2021 | since 2016 | since 2007 | |
|---|---|---|---|
| Revenue | 11.1% | 7.8% | 8.0% |
| Revenue per share | 17.1% | 14.7% | 13.2% |
| Earnings | no data | 7.7% | 8.8% |
| Earnings per share | no data | 14.7% | 14.3% |
| Free cash flow | 6.8% | 6.1% | 8.1% |
| Free cash flow per share | 12.5% | 12.9% | 13.2% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2007 | $92.98B | $963M | $1.23B |
| 2008 | $101.7B | $990M | $513M |
| 2009 | $106.63B | $823M | $959M |
| 2010 | $108.7B | $1.26B | $1.94B |
| 2011 | $112.08B | $1.13B | $1.95B |
| 2012 | $122.73B | $1.4B | $2.55B |
| 2013 | $122.46B | $1.34B | $2.08B |
| 2014 | $137.61B | $1.26B | $2.72B |
| 2015 | $179.05B | $1.48B | $2.57B |
| 2016 | $190.88B | $2.26B | $3B |
| 2017 | $198.53B | $5.18B | $4.18B |
| 2018 | $208.36B | $67M | $3.77B |
| 2019 | $214.32B | $34M | $3.48B |
| 2020 | $231.05B | $900M | $3.87B |
| 2021 | $238.23B | −$4.54B | $3.9B |
| 2022 | $263.97B | $1.11B | $3.9B |
| 2023 | $276.71B | $3.56B | $4.6B |
| 2024 | $308.95B | $3B | $3.63B |
| 2025 | $359.05B | $3.3B | $5.23B |
| 2026 | $403.43B | $4.76B | $5.41B |
Revenue by segment
How McKesson Corporation makes its money and how that has shifted. Names are as the company reports them.
- North American Pharmaceutical$336.7B83%
- Oncology And Multispecialty$48.4B12%
- Medical-Surgical Solutions$11.5B3%
- Prescription Technology Solutions$5.8B1%
The company split earlier years differently. A history would not be comparable, so only 2026 is shown.
Figures as a table
| 2026 | Share 2026 | |
|---|---|---|
| North American Pharmaceutical | $336.65B | 83.4% |
| Oncology And Multispecialty | $48.42B | 12% |
| Medical-Surgical Solutions | $11.51B | 2.9% |
| Prescription Technology Solutions | $5.81B | 1.4% |
| Total revenue | $403.43B | 100% |
Revenue by region
Where McKesson Corporation generates its revenue.
- United States83%
- International17%
Figures as a table
| 2017 | 2018 | 2019 | 2020 | Share 2020 | |
|---|---|---|---|---|---|
| United States | $164.43B | $169.94B | $176.3B | $192.71B | 83.4% |
| International | $34.11B | $38.41B | $38.02B | $38.34B | 16.6% |
| Total revenue | $198.53B | $208.36B | $214.32B | $231.05B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 2 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.